Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is featured in a report issued by PCG Digital Holdings LLC, an affiliate of PCG Advisory Inc. In the report, PCG noted that “Lexaria, delivering active ingredients to patients, could deliver for investors too.” The report stated that LEXX may be poised for a surge as the company’s DehydraTECH(TM) platform has proven to be an effective way to deliver active ingredients. The release noted that DehydraTECH had shown effectiveness as a hypertension treatment using CBD as well as with various antivirals. In addition, the release reported that DehydraTECH-enabled products are currently available in more than 7,000 retail outlets located throughout the United States and that the “book-to-market ratio suggests a great deal of confidence in management.” PCG observed that “LEXX was on an upward trend and trading around $8.50 per share in mid-July, about a dollar away from a 12-month peak. That momentum gave investors the confidence to exercise another $3.8 million in existing warrants and, with the risk of dilution setting in, the stock price retreated to about $5.50. Considering Lexaria’s market cap is still almost $30 million, maybe a one-third drop in share price is a bit too excessive a reaction compared to only a one-tenth expansion in share dilution. And the company appears to have about $12 million in cash, roughly $2 per share. The fundamentals have only changed for the better over the past few months. The company operates an in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patent applications pending around the world. The company is vertically integrated with subsidiaries in the hemp, oral nicotine, and pharmaceutical industries. It should also be noted that the July stock price surge came on the news of DehydraTECH’s efficacy in connection with a colchicine, a COVID-19 therapy.”
To view the full press release, visit https://ibn.fm/L4HWg
About Lexaria Bioscience Corp.
Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
